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Abstract
Background: Death under care is a major challenge for tuberculosis (TB) treatment programs. We derived and
validated a simple score to predict mortality during tuberculosis treatment in high endemicity areas.
Methods: We used data for patients aged ≥15 years, diagnosed and treated for tuberculosis at the Yaounde Jamot
Hospital between January 2012 and December 2013. Baseline characteristics associated with mortality were
investigated using logistic regressions. A simple prognosis score (CABI) was constructed with regression coefficients
for predictors in the final model. Internal validation used bootstrap resampling procedures. Models discrimination
was assessed using c-statistics and calibration assessed via calibration plots and the Hosmer and Lemeshwow (H-L)
statistics. The optimal score was based on the Youden’s index.
Results: A total of 2250 patients (men 57.2%) with a mean age of 35.8 years were included; among whom 213 deaths
(cumulative incidence 9.5%) were recorded. Clinical form of tuberculosis (C), age (A, years), adjusted body mass index
(B, BMI, kg/m2) and status for HIV (Human immunodefiency virus) infection (I) were significant predictors in the final
model (p < 0.0001) which was of the form Death risk = 1/(1 + e− (−1.3120 + 0.0474 ∗ age − 0.1866 ∗ BMI + 1.1637 (if smear negative TB) +
0.5418(if extra − pulmonary TB) + 1.3820(if HIV+))). The c-statistic was 0.812 in the derivation sample and 0.808 after correction for
optimism. The calibration was good [H-Lχ2 = 6.44 (p = 0.60)]. The optimal absolute risk threshold was 4.8%, corresponding
to a sensitivity of 81% and specificity of 67%.
Conclusions: The preliminary promising findings from this study require confirmation through independent external
validation studies. If confirmed, the model derived could facilitate the stratification of TB patients for mortality risk and
implementation of additional monitoring and management measures in vulnerable patients.
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Background
Tuberculosis (TB) is a major cause of death worldwide
[1]. Estimates from the World Health Organisation
(WHO) suggest that about 16% of the 9 million individ-
uals who developed a TB in 2013 died of the disease,
with 95% of these deaths occurring in low- and middle-
income countries [2]. Determinants of death during
treatment for TB have been largely characterised as
recently reviewed by Wait and co-workers [3]. These de-
terminants in developing countries with high endemicity
for TB and high prevalence of HIV infection comprise
essentially the co-infection TB/HIV, severe HIV related
immune-depression, smear negative pulmonary tubercu-
losis (PTB−), under-nutrition and low socio-economic
status [3]. In developed countries, determinants of mor-
tality during TB treatment are mostly non-infectious co-
morbidities, smear positive pulmonary TB (PTB+),
alcohol and drugs abuse [3].
In 2013, Horita and co-workers derived a risk score to
predict mortality in Japanese aged on average 65 years,
receiving in-hospital care for smear positive pulmonary
* Correspondence: pefura2002@yahoo.fr
1Department of Internal medicine and specialities, Faculty of Medicine and
Biomedical Sciences, University of Yaounde 1, Yaounde, Cameroon
2Yaounde Jamot Hospital, P.O Box: 4021, Yaounde, Cameroon
Full list of author information is available at the end of the article
© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Pefura-Yone et al. BMC Infectious Diseases  (2017) 17:251 
DOI 10.1186/s12879-017-2309-9
tuberculosis [4]. However, their cohort did not include
patients with HIV infection, and did not account for
other clinical forms of tuberculosis (PTB− and extra-
pulmonary TB). Furthermore, we are not aware of a
prognostic score integrating all major clinical forms of
tuberculosis, and that has used routinely collected vari-
ables in national TB programs. Healthcare practitioners
need simple and accurate tools to identify at the start of
treatment, those patients with TB who are at high risk of
death during treatment, and whose outcome can be
modified through tailored monitoring and management.
Accordingly, the aim of the present study was to develop
and validate a simple score for predicting the risk of
death during follow-up in patients starting TB treatment




The study was conducted at the Yaounde Jamot Hospital
(YJH), which is a reference hospital for TB and respira-
tory diseases for the Capital City of Cameroon
(Yaounde) and surrounding areas. YJH hosts a diagnosis
and treatment centre for TB (DTC), and an approved
treatment centre for HIV infection (ATC). Over the last
5 years, the DTC of YJH has screened and treated on
average 1400 to 1800 patients each year. All patients
with TB aged ≥ 15 years treated with WHO categories I
or II regimens between January 2012 and December
2013 were retrospectively included in this cohort study.
Patients with missing data on key variables (clinical form
of TB, status for HIV infection, body weight) were ex-
cluded. The study was approved by the institutional
ethic review committee of the Faculty of Medicine and
Pharmaceutical Sciences of the Douala University and
the administrative authorities of the Health Delegation
for the Centre Region.
Classification of TB cases
Diagnosis and classification of TB at the YJH are based
on the WHO’s recommendations and those of the
Cameroon National TB Control Program (NTCP) [5, 6].
The following international definitions are applied at the
DTC: smear-positive pulmonary tuberculosis (PTB+)–
acid-fast bacilli (AFB) present in at least two sputum
specimens; 2) smear-negative pulmonary tuberculosis
(PTB−)–persisting negativity on two sputum examina-
tions after a 10-day course of nonspecific antibiotic
treatment in a patient with clinical and radiological signs
of tuberculosis, in the absence of any obvious cause and
the decision of physician to treat the patient with the full
course of anti-tuberculosis drugs; 3) extra-pulmonary tu-
berculosis (EPTB) – tuberculosis infection involving or-
gans other than the lungs. Patients previously treated
with anti-tuberculosis medications are classified as
retreatment cases and are further sub-classified as “re-
lapse” (i.e. reoccurrence of the disease after a successful
anti-tuberculosis treatment course), “failure”(i.e. positive
smear after 5 months of anti-tuberculosis treatment)
and “treatment after default” (i.e. starting anti-
tuberculosis treatment again after two consecutive
months of interruption). A “new case” refers to a patient
with tuberculosis who has never received anti-
tuberculosis treatment for more than 1 month previ-
ously. “Other cases of tuberculosis” refer to patients not
falling in one of the categories described above. In this
centre, all retreatment cases have been screened for mul-
tidrug resistant tuberculosis by Gene Xpert according to
NTCP guidelines.
Tuberculosis treatment and outcomes
Treatment of patients with active tuberculosis is based
on the NTCP recommendations [5]. Patients are either
hospitalised or treated on an ambulatory basis during
the intensive phase of the treatment. New cases are
treated for 6 months with category I regimens which
comprise a 2-month intensive phase with four anti-
tuberculosis [rifampicin (R), isoniazid (H), ethambutol
(E) and pyrazinamide (Z)] and a 4-month continuation
phase combining rifampicin with isoniazid (2RHEZ/
4RH). Patients undergoing retreatment receive strepto-
mycin (S) in addition under the category II regimen.
Their duration of treatment is 8 months and comprises
2 months of REHZS, 1 month of RHEZ and 5 months of
RHE (2RHEZS/1RHEZ/5RHE). All patients with tuber-
culosis are screened for HIV infection after informed
consent has been obtained from the patient or relative
for dependent patients. HIV-positive patients are pre-
scribed prophylaxis with co-trimoxazole and combined
active antiretroviral therapy (cART) free of charge. Initial
antiretroviral regimens are the combinations lamivudine-
zidovudine-efavirenz or lamivudine-tenofovir-efavirenz.
Antiretroviral therapy was started within 2 weeks follow-
ing HIV diagnosis.
At treatment completion, patients are ranked into the
following mutually exclusive categories [5, 6]: 1) cured–
patient with negative smear at the last month of treat-
ment and at least one of the preceding months; 2) treat-
ment completed–patient who has completed the
treatment and for whom the smear results at the end of
the last month are not available; 3) failure–patient with
positive smear at the 5th month or later during
treatment; 4) death–death from any cause during treat-
ment; 5) defaulter–patient who’s treatment has been
interrupted for at least two consecutive months; 6)
transfer–patient transferred to complete his treatment in
another center and who’s treatment outcome is
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unknown. Cured and treatment completed were consid-
ered as successful treatment.
Data collection
Anti-tuberculosis treatment registers and patients charts
were used for data collection. The following details were
extracted: 1) demographic data including age and sex; 2)
clinical data including hospitalisation during intensive
phase, clinical form of TB (PTB+, PTB−, EPTB), type of
patient (new case, retreatment and other), status for
HIV infection (positive or negative), CD4 count in HIV
positive patients; 3) anthropometric data comprising
weight and adjusted body mass index (BMI) which was
estimated as measured weight divided by the squared of
the average sex-specific height of adult population (1.70
m in men and 1.60 m in women); and 4) the outcome of
patients as treatment success, death, failure, defaulter
and transfer.
Statistical analysis
Data analysis used the R statistical software V.3.1.1 (10-07-
2014) (The R Foundation for Statistical Computing, Vienna,
Austria) and ‘rms’ and ‘pROC’ packages. Data are sum-
marised as count and percentages for categorical variables
and mean (or median) and standard deviation (or 25th–
75th percentiles) for continuous variables. Groups’ compar-
isons used chi square test for categorical variables and Stu-
dent’s t-test and Mann-Whitney U test for continuous
variables. Logistic regressions models were used to derived
the prediction models and were implemented with the lrm
function, which fits binary logistic regression models using
maximum likelihood estimation. Candidate variables were
first tested for inclusion in univariable models, then the sig-
nificant ones based on a p-value < 0.20 were all entered into
the same multivariable models, and backward stepwise
eliminations procedures used to retain the variables in the
final models as recommended by Collett [7]. The linearity
of the effects of continuous predictors was examined using
restricted cubic splines. The performance of the derived
model was tested on the development sample and in boot-
strap resampling, which was based on 2000 replications. In
the bootstrap internal validation based on 2000 replications,
the original dataset was resampled at random with replace-
ment 2000 times, with each random sample being of the
same size (number of participants) as the original dataset.
For each sample, the logistic regressions were fitted, the
new beta coefficients estimated and a new equation derived
using predictors in the final model. This new model was
then tested on the dataset from which it was developed and
as well as on the original dataset, and the differences in the
performance on the derivation and original samples, were
averaged across the 2000 replication to derive the opti-
mism. Model’s discrimination was assessed by calculating
the c-statistic in the derivation sample, and after correction
for optimism in bootstrap internal validation. Model’s cali-
bration was assessed graphically through calibration plots,
and by computing the Hosmer and Lemeshow statistics
(based on n-2 degrees of freedom) [8].
To facilitate the uptake of the model in clinical setting, a
graphical calculator (nomogram) and a risk score table
were constructed by summing up the weighted point-
score from each predictor to arrive at a total score which
can then be used to determine if the patient is at high risk.
For this purpose, receiver-operating characteristic (ROC)
curves were used to derive the optimal cut-off point score,
applying the Youden’s index method [9]. Performance
measures including the sensitivity, specificity, positive and
negative predictive values where then estimated at this op-
timal threshold as well as other selected thresholds.
Results
Data available
Of the 3369 patients treated for TB during the study
period, 384 (11.4%) had missing data on weight and/or
status for HIV, the outcome was unknown in 859 (25.5%)
patients including 567 who were lost to follow-up, 244
who were transferred to other centres and 48 failed on
treatment; they were all excluded. Therefore, the final ana-
lytic sample comprised 2250 patients. The comparative
characteristics of the included and excluded participants
are summarised in Table 1. The mean age and distribution
of type of patients were similar (both p ≥ 0.129), but those
excluded were more likely to be male (p < 0.001) and to
have smear negative tuberculosis (p = 0.008).
Table 1 Study participant characteristics
Characteristics Included patients
N = 2250 (%)
Excluded patients
N = 1119 (%)
p
Gender
Male 1286 (57.2) 742 (66.3) <0.001
Female 964 (42.8) 377 (33.7)
Age, mean (SD) 35.8 (12.7) 36.7 (13.4) 0.144
Initial hospitalization
Yes 1363 (60.6) 495 (45.3) <0.001
No 887 39.4) 597 (54.7)
Clinical form
PTB+ 1527 (67.9) 724 (64.9) 0.008
PTB− 210 (9.3) 143 (12.8)
ETB 513 (22.8) 248 (22.2)
Type of patient
New cases 2119 (94.2) 1037 (92.7) 0.129
Retreatment 106 (4.7) 71 (6.3)
Other 25 (1.1) 11 (1.0)
SD standard deviation, PTB+ smear positive pulmonary tuberculosis, PTB-
smear negative pulmonary tuberculosis, ETB extra-pulmonary tuberculosis
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General characteristics of included participants
The general characteristics of the included participants
are shown in Table 2. Of the 2250 participants included,
1286 (57.2%) were men, and the mean age (standard de-
viation, SD) was 35.8 (12.7) years. Two-third of patients
were PTB+ while 22.8% had extra-pulmonary TB. In all
94.2% of the participants were new cases, while 35% had
HIV infection. For 352 HIV positive patients with CD4
count data available, the median (25th–75th percentiles)
CD4 count was 143 (70–249.75) per mm3.
Determinants of death
Univariable associations of baseline characteristics
with death in treatment are shown in Table 2. A total
of 213 deaths (cumulative incidence 9.5%) was re-
corded during follow-up. Furthermore, 62.9% of
deaths occurred in the early phase of tuberculosis
treatment (<2 months), 29.6% in the late phase, while
in 7.5% of cases, the phase of death was missing. Age
[OR 1.04 (95% CI: 1.03–1.05) per year higher], initial
hospitalisation [1.47 (1.08–1.99)], extra-pulmonary TB
[1.89 (1.36–2.62)], smear negative pulmonary TB [3.32
(2.24–4.91)], HIV infection [5.09 (3.74–6.93)] and ad-
justed BMI [0.83 (0.80–0.87) per kg/m2 higher] were
associated with mortality in univariable analysis; while
gender (p = 0.914) and type of patients (p = 0.393)
were not. In mutually adjusted multivariable analysis,
age, BMI, HIV infection and clinical form of tubercu-
losis (all p < 0.003) remained significantly associated
with mortality and were retained in the final model.
Restricted cubic splines analyses suggested a depart-
ure from linearity of the effects of age and BMI in
both univariable and multivariable analyses. This de-
parture was very modest for age, while the Wald test
(χ2, p-value) was always in favour of very strong lin-
ear effects relative to the nonlinear effect. The χ2 (p-
value) for the Wald test (linear vs. nonlinear terms)
was 55.2 (<0.0001) versus 8.5 (0.037) for age, and
104.3 (<0.0001) versus 22.7 (<0.0001) for BMI in uni-
variable analyses. Equivalents figures in multivariable
analyses were 68.2 (<0.0001) versus 7.8 (0.049) for
age, and 89.1 (<0.0001) vs. 20.1 (<0.0001) for BMI. In
the interest of deriving a simple model for application
in other settings, and to minimise the risk of overfit-
ting from modelling complex terms of age and BMI,
the linearity of the effect was assumed for age and
BMI in the final model. The beta coefficients for this
final model are shown in Table 3. Estimation of the
risk of death based on this final model is provided by
the following equation: Death risk = 1/(1 + e− (−1.3120 +
0.0474 age − 0.1866 BMI + 1.1637 (if smear negative TB) +
0.5418(if extra − pulmonary TB) + 1.3820(if HIV+))).




N = 213 (%)
Treatment success
N = 2037 (%)
Crude OR (95% CI) p-value
Gender 0.914
Male 1286 (57.2) 121 (56.8) 1165 (57.2) 0.94 (0.74–1.31)
Female 964 (42.8) 92 (43.2) 872 (42.8) 1
Age, years 35.8 (12.7) 42.4 (13.5) 35.1 (12.4) 1.04 (1.03–1.05) <0.0001
Adjusted BMI, kg/m2 21.4 (4.0) 19.2 (4.9) 21.6 (3.9) 0.83 (0.80–0.87) <0.0001
Initial hospitalization
Yes 1363 (60.6) 146 (68.5) 1217 (59.7) 1.47 (1.08–1.99) 0.012
No 887 (39.4) 67 (31.7) 820 (40.3) 1
Clinical form <0.0001
PTB+ 1527 (67.9) 107 (50.2) 1420 (69.7) 1
PTB− 210 (9.3) 42 (19.7) 168 (8.2) 3.32 (2.24–4.91)
ETB 513 (22.8) 64 (30.0) 449 (22.0) 1.89 (1.36–2.62)
Type of patient 0.393
New cases 2119 (94.2) 199 (93.4) 1920 (94.3) 1
Retreatment 106 (4.7) 13 (6.1) 93 (4.6) 1.35 (0.74–2.4)
Other 25 (1.1) 1 (0.5) 24 (1.2) 0.40 (0.05–2.99)
HIV serology
Positive 788 (35.0) 149 (69.9) 639 (31.4) 5.09 (3.74–6.93) <0.0001
Negative 1462 (65.0) 64 (30.0) 1398 (68.6) 1
OR odds ratio, BMI body mass index adjusted by divided weight by the square of 1.70m for men and 1.60m for women, SD standard deviation, PTB+ smear
positive pulmonary tuberculosis, PTB- smear negative pulmonary tuberculosis, ETB extra-pulmonary tuberculosis
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Performance of the final model
There was a good agreement between risk of death esti-
mated by the final model and the observed rates of
death, across the continuum of predicted probability
(Fig. 1). The Hosmer and Lemeshow χ2 was 6.44 and the
accompanying p-value was 0.60. The discrimination of
the model in the derivation sample (apparent discrimin-
ation) was good with a c-statistic of 0.812 (95% CI:
0.784–0.841), with only little variability in bootstrap in-
ternal validation (Fig. 2). The optimism from 2000 sam-
ples was 0.0077 corresponding to an optimism-corrected
c-statistic of 0.808. The apparent c-statistic was 0.823
when restricted cubic splines were applied to both age
and BMI in the final multivariable model.
Point scoring system
The nomogram showing the point scores corresponding
to levels of each predictor in the final model is shown in
Fig. 3. The ranged of point scores was 0–22 for age, 0–
50 for BMI, 0–9 for HIV infection and 0–8 for clinical
forms of tuberculosis. The total points ranged from 0 to
80. The optimal point-score for predicting death was
46.5. Corresponding performance measures were 80.7%
(sensitivity), 68.2% (specificity), 21.0% (positive predict-
ive value) and 97.1% (negative predictive value). The per-
formance of the point-scoring system at different
thresholds is summarized in Table 4. The overall per-
formance of the point-scoring system based on the c-
statistic was 0.805 (0.775–0.834). The risk of death in
the form of probability can be obtained from the point-
score via the following formula Death risk = 1/(1 + e
− ((total points − 66.5) 0.1493168)), where 0.1493168 is the lin-
ear predictor unit per point; and 66.5 the scaling factor for
generating only positive point scores. The total points score
can be obtained from linear score by using the formula
total points= 6.6971700 linear predictor score + 66.5.
Additional file 1: Table S1 shows how to estimate the risk
of deaths from the point-scoring system.
Evaluation of the risk of death
Based on the optimal point-score of 46.5 in the deriv-
ation sample, the four levels of risk described in Table 5
were established. Class I corresponds to low risk and
class IV to critical risk. As expected death rate increased
across risk classes, being 1.6, 6.8, 15 and 36.5% respect-
ively for Class I, II, III and IV.
Table 3 Risk factors of tuberculosis death in multivariable
logistic regression model in the derivation data set (based on







Intercept −1.3120 0.5220 0.0120
Age, per 1 year increase 0.0474 0.0061 <0.0001





PTB− 1.1637 0.2202 <0.0001
ETB 0.5418 0.1823 0.0030
HIV serology
Positive 1.3820 0.1677 <0.0001
Negative 0
OR odds ratio, CI confidence interval, BMI body mass index adjusted by
divided weight by the square of 1.70m for men and 1.60m for women, PTB+
smear positive pulmonary tuberculosis, PTB− smear negative pulmonary
tuberculosis, ETB extra-pulmonary tuberculosis


















































Predicted probablity of deathDeciles of predicted probability of death
Observed
Expected
Hosmer & Lemeshow 2=6.44, p=0.60
Fig. 1 Calibration figures of tuberculosis prognostic score
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Discussion
We have derived a model to predict fatal outcomes in
patients starting treatment for tuberculosis in settings of
high endemicity for tuberculosis and HIV infection. The
derived model used easily assessable variables in routine
clinical practice. These predictors were age, clinical form
of tuberculosis, body mass index and status for HIV in-
fection. The model developed and the derived point-
scoring system with these predictors had near perfect
calibration and good discrimination, with only marginal
variation in bootstrap internal validation.
Predictors retained in our final model were essentially
those previously known to be associated with mortality
risk in tuberculosis [10–21]. In both developed and de-
veloping countries, advancing age for instance has been
widely reported to be associated with higher mortality
risk in patients with tuberculosis. Possible reasons for
this association include late diagnosis of TB at the ad-
vanced stage of the disease in older people, unfavourable
living conditions, and comorbidities. Lower BMI is a po-
tent marker of under-nutrition, a well-known determin-
ant of mortality risk in patients with tuberculosis.
Various markers of under-nutrition have been associated
with excess mortality in patients with TB, including low
BMI or body weight and hypoalbuminemia [4], and a
composite score of under-nutrition comprising low BMI,
hypoalbuminemia, hypocholesterolemia, and lymphope-
nia [22].
Available studies have also linked extra-pulmonary TB
with higher risk of mortality [17], with the magnitude of
such risk being two to five times higher when compared
with mortality from smear positive TB. Likewise, smear
negative TB is associated with two to three times higher
mortality rates, relative to smear positive TB [17]. Co-
infection with HIV has also been established as a power-
ful determinant of death in patients with TB, with the
magnitude ranging from two to nearly eight folds when
compared to HIV-free patients [13, 14, 17, 23–27].
We did not test the radiographic predictors. It should
however be recalled that radiographic features of TB
tend to be correlated with indicators of TB severity such
as low BMI [28, 29]. Therefore, loss of discriminatory in-
formation subsequent to not including radiographic pre-
dictors in our model, if any, is likely marginal.
Fig. 2 Discrimination curves of tuberculosis prognostic score
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The final model developed in the current study was
based on four predictors that are routinely assessed in
most tuberculosis control programs in high endemicity
areas. Interestingly, data on those predictors can be ac-
curately collected event by lay people, meaning that the
model will be applicable even in remote and under-
equipped primary care settings. This model had excel-
lent calibration and good discrimination both in the
derivation sample and in bootstrap internal validation.
The observed discriminatory power of the model
(AUC ≥ 0.80) suggest that any drop in this performance
property of the model when applied to other settings,
will need to be sizable to push the model below the un-
acceptable zone (AUC < 0.70); which is very unlikely.
However, due to the anticipated difference in death inci-
dence across settings, it is an expectation that the model
may require some adjustment where appropriate in
order to maintain optimal calibration properties [30].
There are practical examples to support that this adjust-
ment is easily achieved through simple intercept recali-
bration [31].
Our receiver operating characteristic curves analysis
identified the absolute risk threshold of around 5% as es-
timated by the derived model, to be the optimal
Points
0 5 10 15 20 25 30 35 40 45 50
Age (years)
15 25 35 45 55 65 75 85
Adjusted body mass index (kg/m2)
50 45 40 35 30 25 20 15 10
Status for HIV infection
Negative
Positive







0 10 20 30 40 50 60 70 80
Linear Predictor
-9 -8 -7 -6 -5 -4 -3 -2 -1 0 1
Risk of Death
0.001 0.01 0.05 0.1 0.2 0.3 0.4 0.5 0.6 0.7
Fig. 3 Clinical nomogram for patients starting treatment for tuberculosis, estimating the probability of dying on treatment. Instruction for using
the nomogram: Locate the patient’s age on the Age axis. Draw a straight vertical line up to the Points axis to determine how many points the
age of the patient contribute towards the predicted probability of death during TB treatment. Repeat this process for BMI, status for HIV infection
and clinical forms of tuberculosis. Sum the points from each of the predictor to get the total points. Locate the patient’s total points on the Total
points axis. Draw a straight line down to the Risk of death axis to determine the probability of dying during treatment for that patient. The risk of
death is provided as a proportion and should be multiplied by 100 to obtain the value in percentage
Table 4 Performance at different score thresholds of tuberculosis prognostic point scoring
Threshold Risk of death sensitivity specificity Positive predictive value Negative predictive value
46.5 (optimal) 4.8% 80.7 68.2 21.0 97.1
25 0.2% 100 0.6 9.5 100
30 0.4% 99.5 3.7 9.7 98.7
35 0.9% 97.6 20.7 11.4 98.8
40 1.9% 93.4 37.4 13.5 98.2
45 3.9% 85.6 61.5 18.9 97.7
50 7.8% 68.1 76.6 23.3 95.8
55 15.2% 41.8 90.3 31.0 93.7
60 29.0% 17.4 97.5 42.5 91.9
65 44.3% 5.2 99.7 64.7 90.9
70 62.7% 0.9 100 100 90.6
Pefura-Yone et al. BMC Infectious Diseases  (2017) 17:251 Page 7 of 9
threshold to identify at the start of treatments, those pa-
tients with TB who are at increased risk of death during
follow-up. In TB patients scoring above this threshold, ac-
tive investigation and timely management of modifiable co-
factors know to be associated with mortality risk has a po-
tential to improve survival among patients starting TB
treatment. Such co-factors include and are not restricted to
under-nutrition, anaemia and opportunistic diseases. Con-
sidering that TB tend to predominantly affect socially de-
prived people [32, 33], early nutritional support should be
an integral component of TB treatment programs. Simi-
larly, early introduction of antiretroviral therapy has been
shown to reduce the risk of death by about 68% in TB pa-
tients co-infected with HIV [34].
A sizable proportion of potentially eligible participants
had missing data on the outcome of candidate predictors of
interest and was excluded. While data imputation technics
could be used to fill the missingness and possibly using data
from all eligible participants, implementing some steps of
predictive models development on imputed data is not
straightforward [35]. However, the similarity of profiles be-
tween excluded participants and those in the final analytic
sample suggest that the derived estimates are likely un-
biased. By using bootstrap resampling for internal valid-
ation, we were able to use all participants with valid data
for model development, therefore achieving a very high
number of outcomes per candidate variable tested, and ac-
cordingly a very good statistical power [35]. In the absence
of individual level data on height, the adjusted BMI was
used as predictor in our model. By constraining the height
to assume the same gender-specific value in all participants,
we have possibly reduced to some extent the variability in
the true BMI across participants, which in turn could lead
to non-optimal extraction of predictive information from
BMI. However the overall good discriminatory power
achieved using this imperfect BMI suggests that further gain
from using the true BMI will likely be marginal. The non-
appreciable difference in discriminatory powers between our
final model and a model accounting for possible non-
linearity of the effect of age and BMI through restricted
cubic splines, confirms that essential discriminatory infor-
mation from the two predictors are captured by the linear
forms. This supports our choice of a simplified final model
assuming a linear functional form of the two predictors.
Conclusions
We have developed a simple risk score based on four
routinely collected variables in TB program, to estimate
the chance of death in patients commencing TB treat-
ment in high endemicity areas for TB and HIV infection.
This model had good performance in the derivation
sample and during internal validation using bootstrap
resampling methods. Successful application of this
model in routine TB care settings can assist the identifi-
cation of a group of patients whose risk of fatal outcome
can potentially be modify through identification and cor-
rection of co-factors of mortality in TB. To promote the
uptake of the model in routine setting, we have devel-
oped a graphical calculator in the form of a nomogram
as well as a point scoring system to allow risk estimation
of the model without manipulating complex formula.
The model is hereafter called CABI, reflecting the four
variables in the models: C for ‘clinical form of tubercu-
losis’, A for ‘age’, B for ‘body mass index’ and I for ‘status
for HIV infection’. Just like any newly developed model,
results from this study are just preliminary findings.
CABI will require independent external validation to es-
tablish the performance both in the study setting and in
other settings including African, Latin America and
Asian populations [36], before recommendation for up-
take in routine clinical setting.
Additional file
Additional file 1: Table S1. Point scoring for a death prediction score
in tuberculosis patients. (DOCX 19 kb)
Abbreviations
BMI: Body mass index; cART: combined active antiretroviral therapy;
DTC: Diagnosis and treatment centre for TB; E: Ethambutol; EPTB: Extra-
pulmonary tuberculosis; H: Isoniazid; HIV: Human immunodefiency virus; H-
L: Hosmer and Lemeshwow; NTCP: Cameroon National TB Control Program;
PTB−: Smear negative pulmonary tuberculosis; PTB+: Smear positive
pulmonary TB; R: Rifampicin; ROC: Receiver-operating characteristic;






Table 5 Discriminative performances of tuberculosis simple
prognostic score (CABI) and risk categories
Parameters Values
Linear predictor score (CABI), mean (standard
deviation)
−2.89 (1.31)
C-statistic by linear predictor score (CABI) (95% CI) 0.812 (0.784–
0.841)
C-statistic by risk group 0.788 (0.758–
0.818)
Mortality in each risk group
Class I, low risk, Total points < 46 16/1029 (1.6%)
Class II, moderate risk, 46 ≤ Total points < 50 25/366 (6.8%)
Class III, high risk , 50 ≤ Total points < 60 106/674 (15%)
Class IV, critical risk , Total points≥ 60 66/181 (36.5%)
CABI, derived from clinical form of tuberculosis (C), Age (A), Body mass index
(B), I (HIV infection)
Death risk = 1/(1 + e− (−1.3120 + 0.0474 ∗ age − 0.1866 ∗ BMI + 1.1637(if smear negative TB) +
0.5418(if extra − pulmonary TB) + 1.3820(if HIV+)))
Total points = 6.6971700 ∗ linear predictor score + 66.5
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